Cel-Sci Corp. (CVM)
XASE:CVM
Want to see CVM full AI Analyst Report?
CVM Stock Chart & Stats
$5.19
-$0.03(-7.92%)
At close: 4:00 PM EST
$5.19
-$0.03(-7.92%)
Day’s Range― - ―
52-Week Range$1.57 - $13.48
Previous Close$0.36
Volume1.47M
Average Volume (3M)125.69K
Market Cap
$14.29M
Enterprise Value$15.96M
Total Cash (Recent Filing)$6.28M
Total Debt (Recent Filing)$10.63M
Price to Earnings (P/E)―
Beta1.87
Next Earnings
May 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.13
Shares Outstanding8,457,967
10 Day Avg. Volume66,836
30 Day Avg. Volume125,686
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.34
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap1.12
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.14
Enterprise Value/Ebitda-0.82
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-4.16
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Contract Manufacturing & GMP FacilitiesOwning GMP manufacturing and cell/gene bioprocessing capabilities creates a durable, non‑clinical revenue channel. Service contracts can produce milestone and batch-based revenue, diversify funding beyond equity raises, and build customer relationships that persist through cycles.
Narrowing Net Losses / Expense ControlConsistent reduction in annual net losses over multiple years signals better cost discipline and structural expense control. If sustained, this reduces future financing needs, extends runway, and improves the firm's ability to invest selectively in trials or manufacturing without immediate dilution.
Clinical-stage Lead Candidate (Multikine)A progressing clinical candidate provides a clear path to value creation via approval, licensing, or partnering. Multikine’s targeted indication and pre‑SOC use could enable unique positioning in head and neck oncology and create durable commercial or royalty revenue if trials and regulatory steps succeed.
Bears Say
Pre-revenue Status And Ongoing Cash BurnRemaining pre‑revenue makes operations dependent on external financing; persistent losses and negative free cash flow mean recurring dilution or debt issuance is likely. That reliance constrains long‑term strategic flexibility and increases execution risk over the next several quarters.
Extreme 2025 Leverage OutlierAn anomalous, massive reported debt position materially increases refinancing and solvency risk if accurate. Even as an outlier, such volatility undermines stakeholder confidence, complicates partnerships and candidate commercialization, and could trigger covenant or liquidity crises.
Operating Cash Flow Volatility & Negative OCFSustained negative operating cash flow requires persistent external funding; the extreme 2025 number raises data reliability concerns but underscores cash generation weakness. Limited internal cash generation reduces ability to fund trials or scale manufacturing without material external support.
Cel-Sci News
CVM FAQ
What was Cel-Sci Corp.’s price range in the past 12 months?
Cel-Sci Corp. lowest stock price was $1.57 and its highest was $13.48 in the past 12 months.
What is Cel-Sci Corp.’s market cap?
Cel-Sci Corp.’s market cap is $14.29M.
When is Cel-Sci Corp.’s upcoming earnings report date?
Cel-Sci Corp.’s upcoming earnings report date is May 14, 2026 which is in 9 days.
How were Cel-Sci Corp.’s earnings last quarter?
Cel-Sci Corp. released its earnings results on Feb 18, 2026. The company reported -$0.68 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.68.
Is Cel-Sci Corp. overvalued?
According to Wall Street analysts Cel-Sci Corp.’s price is currently Overvalued.
Does Cel-Sci Corp. pay dividends?
Cel-Sci Corp. does not currently pay dividends.
What is Cel-Sci Corp.’s EPS estimate?
Cel-Sci Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cel-Sci Corp. have?
Cel-Sci Corp. has 8,457,967 shares outstanding.
What happened to Cel-Sci Corp.’s price movement after its last earnings report?
Cel-Sci Corp. reported an EPS of -$0.68 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.368%.
Which hedge fund is a major shareholder of Cel-Sci Corp.?
Currently, no hedge funds are holding shares in CVM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Cel-Sci Corp.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC; CEL-2000 and CEL-4000 are product candidates for the treatment of rheumatoid arthritis; and LEAPS COV-19, a product candidate to treat COVID-19 coronavirus. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.
Technical Analysis
Ownership Overview
2.55% Insiders
3.70% Mutual Funds
0.02% Other Institutional Investors
90.93% Public Companies and
Individual Investors